ArticlePloS one2008
Precancerous stem cells can serve as tumor vasculogenic progenitors.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 104 citations in OpenAlex.
- Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.Cell research · 2011Trial
- Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.Frontiers in immunology · 2025Review
- Defining precancer: a grand challenge for the cancer community.Nature reviews. Cancer · 2024Review
- Can precancerous stem cells be risk markers for malignant transformation in the oral mucosa?Cellular & molecular biology letters · 2023Article
- Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.Molecular carcinogenesis · 2022Article
- A novel tumor-specific broad-spectral monoclonal antibody to PL2L60 is highly effective for the treatment of various types of cancers from human and mouse.American journal of cancer research · 2022Article
- Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells' Role in Tumor Progression.Stem cell reviews and reports · 2022Review
- Review
- The Cancer Stem Cell in Hepatocellular Carcinoma.Cancers · 2020Review
- Onco-Esthetics Dilemma: Is There a Role for Electrocosmetic-Medical Devices?Frontiers in oncology · 2020Review
- Expression of PIWIL2 in oral cancer and leukoplakia: Prognostic implications and insights from tumors.Cancer biomarkers : section A of Disease markers · 2019Article
- High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer.Medicine · 2017Observational
- Therapeutic resistance and cancer recurrence mechanisms: Unfolding the story of tumour coming back.Journal of biosciences · 2016Review
- The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis.Stem cell reviews and reports · 2015Review
- Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.European journal of clinical pharmacology · 2015Article
- Cancer stem cells: a potential target for cancer therapy.Cellular and molecular life sciences : CMLS · 2015Review
- Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.Journal of experimental & clinical cancer research : CR · 2015Article
- Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.Oncotarget · 2015Article
- Metabolic control of cancer cell stemness: Lessons from iPS cells.Cell cycle (Georgetown, Tex.) · 2015Review
- Vascular remodeling in cancer.Oncogene · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor neo-vascularization is critical for tumor growth, invasion and metastasis, which has been considered to be mediated by a mechanism of angiogenesis. However, histopathological studies have suggested that tumor cells might be the progenitor for tumor vasculature. Recently, we have reported that the precancerous stem cells (pCSCs) representing the early stage of developing cancer stem cells (CSCs), have the potential for both benign and malignant differentiation. Therefore, we investigated whether pCSCs serve as progenitors for tumor vasculogenesis. Herein, we report that in the pCSC-derived tumors, most blood vessels were derived from pCSCs. Some pCSCs constitutively expressed vasculogenic receptor VEGFR-2, which can be up-regulated by hypoxia and angiogenesis-promoting cytokines, such as GM-CSF, Flt3 ligand, and IL-13. The pCSCs are much more potent in tumor vasculogenesis than the differentiated tumor monocytic cells (TMCs) from the same tumor, which had comparable or even higher capacity to produce some vascular growth factors, suggesting that the potent tumor vasculogenesis of pCSCs is associated with their intrinsic stem-like property. Consistently tumor vasculogenesis was also observed in human cancers such as cervical cancer and breast cancer and xenograft lymphoma. Our studies indicate that pCSCs can serve as tumor vasculogenic stem/progenitor cells (TVPCs), and may explain why anti-angiogenic cancer therapy trials are facing challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.